Cite
HARVARD Citation
Van Cutsem, E. et al. (2019). Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single‐Arm, Open‐Label Phase IIIb CONSIGN Study. Oncologist. pp. 185-192. [Online].